The FDA has published a formal notice proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, a move that would close the high-volume compounding pathway that supplied much of the low-cost GLP-1 market during the 2023–2025 shortage era.
The public comment window on the proposal closed at 11:59 p.m. ET on July 30, 2026, and the administrative record is now shut. The agency has not announced a decision timeline, with a final rule likely in late 2026 to early 2027.
The proposal, if finalized as written, would reshape the U.S. compounded GLP-1 supply chain and force telehealth operators and 503B outsourcing facilities to source from approved drug products or find alternative compounding routes.
What happened
The FDA’s proposal targets three of the most widely compounded GLP-1 drugs: semaglutide, tirzepatide, and liraglutide. Under current rules, 503B outsourcing facilities can compound drugs from bulk active pharmaceutical ingredients (API) if those substances appear on the FDA’s Bulks List. A permanent exclusion would remove that authority for these three drugs regardless of shortage status.
The public comment period closed on July 30, 2026. No further public input is being accepted, and the administrative record is closed. The FDA has not indicated when it expects to issue a final rule.
Notably, the three drugs are at different stages in the FDA’s shortage framework. Tirzepatide came off the FDA shortage list in December 2024, and semaglutide followed in February 2025. Liraglutide remains on the shortage list, which gives it a separate compounding pathway independent of the 503B Bulks List proposal.
Why it matters
If finalized as proposed, this rule would permanently close the main regulatory door that allowed 503B outsourcing facilities to compound GLP-1 drugs from bulk API without being tied to a shortage determination. During the 2023–2025 shortage period, this pathway was a primary source of lower-cost compounded GLP-1 medications for patients whose insurance did not cover branded products.
The affected groups include:
- 503B outsourcing facilities that compound GLP-1s from bulk API
- Telehealth companies selling compounded GLP-1 formulations
- Peptide compounders relying on the 503B bulk pathway
- GLP-1 consumers currently using compounded formulations
- Insurance-uncovered patients who have relied on lower-cost compounded options
For telehealth operators, the practical effect would be a need to source from FDA-approved drug products or identify alternative compounding routes that remain legally available. For consumers, the proposal could reduce access to the lower-cost compounded GLP-1 products that expanded widely during the shortage era.
It is important to note that this remains a proposal. No final rule has been issued, and the FDA has not announced a decision timeline.
What to watch next
- Final rule timing: The FDA has not committed to a date, but a final rule is likely in late 2026 to early 2027.
- Liraglutide shortage status: Because liraglutide remains on the FDA shortage list, it retains a separate compounding pathway for now. Any change to its shortage designation would affect that pathway.
- Telehealth and 503B responses: Outsourcing facilities and telehealth companies may shift sourcing strategies, pursue alternative compounding routes, or adjust product offerings in anticipation of a final rule.
Sources
Industry information only. Not medical or legal advice.
